
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. has a positive outlook driven by several fundamental factors, including faster-than-expected growth in the spine market and increased sales from its Enabling Technologies segment, which contribute to higher expected margins. The company is also positioned to see strong free cash flow and improved organic growth, supported by an optimistic revenue guidance that may lead to incremental multiple expansion. Additionally, with ongoing initiatives like the NuVasive integration and in-sourcing manufacturing, there is potential for meaningful gross margin expansion and stabilization of EBITDA margins to around 34-35% by 2026.
Bears say
The negative outlook on Globus Medical's stock is primarily driven by potential risks associated with slower-than-expected growth in the spine market and possible revenue disruptions stemming from ongoing mergers with NuVasive and Nevro. Additional concerns include expectations for low-single-digit revenue growth with flat margins, alongside potential challenges in competitive dynamics and sluggish performance of key product launches in the enabling technologies segment. Furthermore, the capital environment may adversely impact robotic purchasing, which could lead to additional downward risks for future revenue estimates and overall financial performance.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares